Information for the public

Olaparib (Lynparza) with bevacizumab (Avastin) is available on the NHS as a possible maintenance treatment for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults. You can have it if your cancer:

  • has completely or partially responded to first-line platinum-based chemotherapy with bevacizumab
  • is advanced and
  • has a mutation on the BRCA1 or BRCA2 gene or genomic instability, which means gene mutations are more likely.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.

Questions to think about

  • How well does it work compared with other treatments?
  • What are the risks or side effects? How likely are they?
  • How will the treatment affect my day-to-day life?
  • What happens if the treatment does not work?
  • What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS webpage on ovarian cancer may be a good place to find out more.

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5685-2

This page was last updated: